In a recent study, the Food and Drug Administration has given green signal to a drug which can cure cystic fibrosis. However, the drug, Kalydeco, from Vertex Pharmaceuticals Inc., would not be that easy to get as it may cost one to shell out as much as $294,000 a year.

Vertex Pharmaceuticals is revealed to post results from the first phase III study of its experimental hepatitis C drug telaprevir sometime this quarter.

The first telaprevir data to be issued will come from the phase III study known as ADVANCE. The study is revealed to involve treatment-naïve hepatitis C patients.

After closely observing the hepatitis C drug Telaprevir in a study, Vertex Pharmaceuticals Inc., has confirmed that it works well when administered twice daily as well, instead of the earlier believed dosage of thrice daily. The study confirmed that the drug worked in over 80% of the patients when given two times a day as well.